Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated (LGND) Actualités

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:LGND

1 2 3 4 5 6 7 8 9 10 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
07/03/2024	19h27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
06/03/2024	00h12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
01/03/2024	22h09	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
29/02/2024	22h49	Edgar (US Regulatory)	Form 144/A - Report of proposed sale of securities: [Amend]	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
27/02/2024	13h24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
14/02/2024	12h26	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
13/02/2024	21h39	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
11/01/2024	01h30	GlobeNewswire Inc.	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
05/01/2024	23h40	Dow Jones News	Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
01/12/2023	14h20	GlobeNewswire Inc.	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
28/11/2023	15h01	GlobeNewswire Inc.	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
10/11/2023	03h48	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
09/11/2023	23h03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
06/11/2023	15h00	GlobeNewswire Inc.	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
18/10/2023	14h00	GlobeNewswire Inc.	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
02/10/2023	15h00	GlobeNewswire Inc.	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
26/09/2023	00h12	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
17/07/2023	14h45	GlobeNewswire Inc.	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
29/06/2023	15h00	GlobeNewswire Inc.	Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
21/06/2023	15h29	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
09/06/2023	23h01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
05/06/2023	15h01	GlobeNewswire Inc.	Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
25/05/2023	23h00	GlobeNewswire Inc.	Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
16/05/2023	19h15	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
08/05/2023	22h08	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
26/04/2023	18h25	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
20/04/2023	22h10	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
20/04/2023	22h08	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
20/04/2023	22h08	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated
22/02/2023	22h01	Business Wire	Ligand Reports Fourth Quarter and Full Year 2022 Financial Results	NASDAQ:LGND	Ligand Pharmaceuticals Incorporated

Showing the most relevant articles for your search:NASDAQ:LGND

1 2 3 4 5 6 7 8 9 10 Suivant >>

Societe Generale

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales